Vir Biotechnology EBITDA vs. Number Of Shares Shorted

VIR Stock  USD 8.72  0.37  4.43%   
Based on the key profitability measurements obtained from Vir Biotechnology's financial statements, Vir Biotechnology may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Vir Biotechnology's ability to earn profits and add value for shareholders.
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-664.9 M
Current Value
-631.6 M
Quarterly Volatility
383.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
As of 12/10/2024, Price To Sales Ratio is likely to drop to 14.87. In addition to that, Days Sales Outstanding is likely to drop to 207.66. At this time, Vir Biotechnology's Net Interest Income is relatively stable compared to the past year. As of 12/10/2024, Interest Income is likely to grow to about 86.5 M, though Operating Income is likely to grow to (650.1 M).
For Vir Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vir Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vir Biotechnology utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vir Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vir Biotechnology over time as well as its relative position and ranking within its peers.
  

Vir Biotechnology's Revenue Breakdown by Earning Segment

Check out World Market Map.
To learn how to invest in Vir Stock, please use our How to Invest in Vir Biotechnology guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vir Biotechnology. If investors know Vir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vir Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.585
Earnings Share
(3.93)
Revenue Per Share
0.579
Quarterly Revenue Growth
(0.1)
Return On Assets
(0.19)
The market value of Vir Biotechnology is measured differently than its book value, which is the value of Vir that is recorded on the company's balance sheet. Investors also form their own opinion of Vir Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Vir Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vir Biotechnology's market value can be influenced by many factors that don't directly affect Vir Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vir Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vir Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vir Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Vir Biotechnology Number Of Shares Shorted vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Vir Biotechnology's current stock value. Our valuation model uses many indicators to compare Vir Biotechnology value to that of its competitors to determine the firm's financial worth.
Vir Biotechnology is rated below average in ebitda category among its peers. It also is rated below average in number of shares shorted category among its peers . Vir Biotechnology reported last year EBITDA of (664.85 Million). Comparative valuation analysis is a catch-all technique that is used if you cannot value Vir Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Vir Number Of Shares Shorted vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Vir Biotechnology

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(664.85 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Vir Biotechnology

Shares Shorted

 = 

Shorted by Public

+

by Institutions

 = 
5.51 M
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.

Vir Number Of Shares Shorted Comparison

Vir Biotechnology is currently under evaluation in number of shares shorted category among its peers.

Vir Biotechnology Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Vir Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vir Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of Vir Biotechnology's change in net profit over the period of time. It can combine multiple indicators of Vir Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-815 K-855.8 K
Net Interest Income82.4 M86.5 M
Interest Income82.4 M86.5 M
Operating Income-684.3 M-650.1 M
Net Loss-600.7 M-570.7 M
Income Before Tax-628.2 M-596.8 M
Non Operating Income Net Other148.4 M155.8 M
Total Other Income Expense Net56.1 M63.9 M
Net Income Applicable To Common Shares593.2 M622.9 M
Net Loss-615.1 M-584.3 M
Income Tax Expense-13.1 M-12.4 M
Change To Netincome546.6 M573.9 M
Net Loss(4.59)(4.36)
Income Quality 1.27  0.86 
Net Income Per E B T 0.98  1.02 

Vir Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Vir Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vir Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vir Biotechnology's important profitability drivers and their relationship over time.

Use Vir Biotechnology in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vir Biotechnology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vir Biotechnology will appreciate offsetting losses from the drop in the long position's value.

Vir Biotechnology Pair Trading

Vir Biotechnology Pair Trading Analysis

The ability to find closely correlated positions to Vir Biotechnology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vir Biotechnology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vir Biotechnology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vir Biotechnology to buy it.
The correlation of Vir Biotechnology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vir Biotechnology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vir Biotechnology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vir Biotechnology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Vir Biotechnology position

In addition to having Vir Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Treasury ETFs Thematic Idea Now

Treasury ETFs
Treasury ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Treasury ETFs theme has 114 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Treasury ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Vir Stock Analysis

When running Vir Biotechnology's price analysis, check to measure Vir Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vir Biotechnology is operating at the current time. Most of Vir Biotechnology's value examination focuses on studying past and present price action to predict the probability of Vir Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vir Biotechnology's price. Additionally, you may evaluate how the addition of Vir Biotechnology to your portfolios can decrease your overall portfolio volatility.